FlashFeed

Full text

It's July, I'm fresh off writing my 2026 cameras half-year review , and in the process something became clear to me — neither Nikon nor Fujifilm has released a new camera this year (the Instax mini Evo Cinema instant camera doesn't count).

So while I've personally tested standout models from other manufacturers in recent months, such as the Sony A7R VI and Canon EOS R6 Mark III mirrorless cameras, plus the Ricoh GR IV and Panasonic Lumix L10 premium compacts, we're yet to see new Z-mount or X-mount bodies.

I'm sure the question on many a camera fan's lips is this: can we expect new Nikon and Fujifilm cameras later this year?

I've reviewed every major camera release over the last few years, attended countless events, and have studied the timeline and cadence of previous releases to form a picture of what could happen next.

I've considered which bodies could be due for an upgrade, and what direction each brand has been headed recently. So let's see what could happen next for 2026's quiet camera manufacturers, Nikon and Fujifilm.

Nik-none?

The last Nikon camera body was the Nikon Zr from September 2025, which was its first cinema camera co-branded with RED. It packed super-impressive video specs, many of which were borrowed from the superb Z6 III , into a particularly small body with an epic 4-inch touchscreen and stellar audio features.

For a true mirrorless hybrid with viewfinder, we need to go even further back, over a year in fact, to the Nikon Z5 II in May 2025. This was a decent upgrade of Nikon's affordable Z5, which delivered a raft of performance improvements to redefine what entry-level full-frame models can do, and went on to bag our Camera of the Year 2025 award.

Currently, the range of Nikon cameras includes the Nikon Z30, Z fc and Z50 II APS-C bodies, and the Z5 II, Z6 III, Z f, Z7 II, Z8 and Z9 full-frame bodies, plus the ZR cinema body.

The Nikon ZR was the first Nikon / RED co-branded camera, and I expect other models to follow next (Image credit: Tim Coleman) The most heavily rumored Nikon cameras are the Nikon Z9 II — what with the Z9 being over four years old — and new cinema camera bodies; potentially a premium and larger option with pro-grade connectivity that could sit above the ZR, plus an even more affordable version with an APS-C sensor.

We could get a new Z f-series model — both of the retro-styled bodies have been around for a while now. Personally, I'd like to see a Nikon camera in the Z f style, but as a compact camera version with a fixed fast aperture prime lens.

Tipsters believe we're unlikely to see another Z7 camera; the Z6 III (and obviously the Z5 II) is too recent for a replacement, while the Z8 has aged well and still holds its own today. CoolPix compact cameras have seemingly been sunsetted — besides refreshing its old 125x zoom bridge camera with the CoolPix P1100 , we haven't seen a true new CoolPix in several years.

For me, having been hosted by Nikon at IBC 2025 in Amsterdam last September around the launch of the ZR, it was clear that Nikon has its head in cinema camera gear, so a high-end cinema body to follow the ZR is highly plausible, though I don't know what it would be called.

A new Nikon cinema camera with an APS-C sensor is also highly likely. In theory, it would effectively render a direct Z30 successor redundant, although it would cost a fair whack more than a potential Z30 II would. That would be a shame — the Z30 is Nikon's cheapest mirrorless camera, and Nikon has otherwise largely ignored truly affordable cameras for beginner photographers.

Fujifilm's next generation processor inbound?

As for Fujifilm cameras , the X-T30 III was its most recent X-mount release, back in October 2025, which followed the classy X-E5 from June 2025.

Those launches meant that practically every current X-mount model is fitted with Fujifilm's latest X-Processor 5 chip, besides the X-Pro series, with a range of 26MP and 40MP options.

I wouldn't bank on an X-Pro 4 until the next generation of processor is out in the wild, if at all, and usually each new processor comes with the latest high-end X-T model, the most recent of which was the X-T5 .

The wacky Fujifilm X-Pro 3 with its film simulation window and hidden rear LCD is among the X-series cameras most due a successor (Image credit: Future) It comes as no surprise then that the X-T6 is the most-rumored Fujifilm camera, which is being tipped for a September release when Fujifilm typically hosts its once- or twice-yearly X-Summit.

I've written about what upgrades I'd hope for in an X-T6 , especially improved autofocus performance and an all-new processor, but otherwise it's hard to see where Fujifilm can better the X-T5 without treading on the toes of the high-speed XH-series.

Elsewhere in the range, the X100VI premium compact continues to sell well, and so I'd be really surprised if a seventh generation model comes this year — a new processor needs to come first, too.

Stepping outside of new gear and into photography, it's worth noting that Fujifilm recently shared its new 'Look Up' campaign (see below), encouraging people to look up from their screens and connect with the world around them, saying:

'Our cameras bring you back into the moment, giving you agency over how you see, how you feel and how you remember. They allow you to turn emotions into images — a grounding force that doesn’t tell you what to think, but helps you stay focused and present.'

Are you a Nikon or Fujifilm photographer? Which camera would you like to see next, and what are the upgrades that would benefit your photography the most? Have your say in the comments.

Full text

Want to speed up your recovery after an injury or a workout? Some influencers are fans of shots of BPC-157 and TB-500 for that. Want scar-free, youthful skin and thick hair? Reddit posts rave about GHK-Cu and KPV. Want to build beautiful, bulky biceps? Some fitness influencers swear shots of ipamorelin will do wonders. This is the world of peptides — an assortment of chemicals that promise to boost your body and health — and people are self-injecting them in a growing wellness trend.

Promoted by bodybuilders and influencers, supporters of the "Make America Healthy Again" movement and Silicon Valley early adopters, peptides promise results that leave people better than well, fitter than fit. Yet despite getting glowing reviews on social media, most peptides have limited clinical evidence to support health benefits, whether it's helping to heal a rotator cuff injury, improving libido or building muscles. There's not much information out there on the drugs' effectiveness and even less on their safety.

In 2023 the Food and Drug Administration banned several peptides, including BPC-157, GHK-Cu, KPV and ipamorelin, from being produced in the U.S. by compounding pharmacies — facilities that legally make non-FDA-approved medications for individual use — because of " significant safety risks ." Many peptides are imported from outside of the country, and many made here are marketed for research use only. People who desperately want the promise contained in the tiny vials seek them out on online on legally dubious gray markets.

But accessing the shots might soon get easier. On the podcast The Joe Rogan Experience on February 27, Robert F. Kennedy, Jr., secretary of the Department of Health and Human Services, proposed legalizing the compounding of 14 peptides — and the FDA seems poised to grant his wish. Earlier this week the agency released plans to hold a meeting with independent advisers in July to review whether some U.S. pharmacies should be allowed to manufacture certain peptides , including BPC-157, TB-500 and KPV.

If the lift on peptides happens, a flood of people could start using the drugs , regardless of any safety concerns.

A Peptide by Many Names

A peptide is a chain of two or more amino acids — building blocks of proteins . The body's cells can produce numerous peptides, which perform various tasks or serve as signaling molecules.

Insulin is a peptide. So is human growth hormone — and semaglutide , the active ingredient in glucagonlike peptide 1 (GLP-1) receptor agonist drugs such as Ozempic and Wegovy . (GLP-1s are FDA-approved for managing type 2 diabetes and for weight loss). Buzzy new injections such as BPC-157 and GHK-Cu — touted for tissue repair — are derivations or synthetic versions of naturally occurring peptides. The public and online health retailers are starting to use "peptides" as a catchall term for any chemical taken for well-being, energy, exercise recovery, and more, says Luke Turnock, a criminologist who studies how people use enhancement drugs at the University of Lincoln in England.

And while people are using them as treatments, peptides aren't often described as drugs. "'Drug' has a certain stigma or negative connotation attached to it," Turnock says. The popularity of peptides has its roots in the bodybuilding and powerlifting communities, he explains, where "drug" has historically been tied to steroids — which are generally banned for professional athletes.

The term "peptides," meanwhile, stresses the natural origin of the molecules, says Flynn McGuire, who studies sports medicine at the University of Utah. "Because it's 'natural,' it is better or different, even though they're just drugs," McGuire says.

A Surge in Popularity

In the past few years, orthopedic surgeon Omar Rahman has seen a spike in interest in peptides. "I'm seeing more patients asking about peptides, often driven by the longevity and wellness space," says Rahman, who practices at Pacific Coast Sports Medicine in Los Angeles.

Because peptides encompass many products — some available by prescription, others on the gray market — the exact number of people trying them is hard to pin down. The subreddit r/peptides currently has more than 70,000 weekly visitors, and the related subreddit r/biohackers, which frequently hosts conversations on peptides, has more than 600,000. A scroll through TikTok offers pages of people sharing their "stacks" — combinations of injections people take to meet their personal goals, from muscle-building and exercise recovery to increased brainpower or a better tan.

"The real cultural tipping point in my mind seems to have been around 2022, when the GLP-1s really blew up," says Turnock, who is researching the peptide boom. He says injecting drugs became "normalized" when GLP-1 drugs approved to treat diabetes, such as Ozempic, were also shown to be effective for weight loss — and eventually became an approved treatment for obesity.

Some are turning to peptides because they feel doctors aren't giving them the help they need, says Dan Cushman, a sports medicine doctor at the University of Utah. Injuries to certain tissues, such as tendons, "are very slow to heal" with conventional treatments, he says. Mainstream treatment can also be expensive and painful. To someone desperate for relief, peptides might seem worth a try.

Peptide use is also linked to a growing interest in health autonomy, Turnock says. This is the idea "that doctors, if they're not prescribing what you ask for or they're not offering you these solutions, are acting as a barrier to your good health."

Stacking Up

McGuire, Cushman and colleagues published a review last year on one peptide they encountered frequently: BPC-157. The peptide is promoted as a way to stimulate multiple cellular pathways involved in blood vessel formation, cell growth, muscle repair and inflammation. Their review, however, found that most of the evidence of such health effects was from rodent studies , and only three small pilot studies had looked at BPC-157 use in humans.

In a regimen called the "Wolverine" stack, many people combine BPC-157 with injections of TB-500, another peptide that is supposed to promote healing but has even less research behind it. The "Wolverine" stack is named after the rapidly healing X-Men character. Add injections of GHK-Cu and KPV, and the stack is called "glow" or "KLOW." People claim that GHK-Cu increases wound healing, decreases scarring and helps regenerate collagen — and that KPV, derived from a hormone naturally found in the body, reduces inflammation. GHK-Cu is found in blood plasma and is an FDA-approved ingredient in topical antiaging cosmetics — but it is currently banned as an injectable because of safety concerns, such as the risk of immune reactions caused by impurities.

For muscle-building, the peptides ipamorelin and CJC-1295 are advertised as stimulating growth hormone release. Both have little clinical evidence behind them, however. Some people stack ipamorelin with GLP-1 drugs to try to lose fat while building muscle, though the effects of taking these injections together have not been studied.

Use at Your Own Risk

Clinical trial data for most of these peptides are thin. Not only are the effects anecdotal, but so are the doses. FDA-approved drugs, Cushman says, have been tested and reviewed not just for their efficacy but also for their safety. There is very little existing information on most of these peptides, he says, let alone on what happens if they are combined.

In many cases, the provenance of these peptides is even grayer than the gray market would suggest. "Patients are accessing peptides through online vendors, wellness clinics and compounding pharmacies," Rahman says. "That variability in sourcing is one of the biggest concerns, particularly when it comes to purity, dosing consistency and overall quality control."

The FDA does not allow production of BPC-157, GHK-Cu, KPV and ipamorelin in the U.S., for example, by compounding pharmacies because of safety concerns , so people are ordering them from overseas — usually from China. Some are buying peptides labeled as "for research only." Not all are stuck in the legal gray areas; other peptides are available from compounding pharmacies .

In Kennedy's February remarks about his aim to allow compounding of more than a dozen peptides in the U.S., he suggested that peptides made within the country would be safer than ones acquired abroad.

RELATED STORIES

'It's being promoted like there's absolutely no risk': Why some experts say melatonin should be considered a drug rather than a supplement

Ozempic in a pill? New oral drug may work as well as Ozempic-style injectables

Ozempic-style drugs tied to more than 60 health benefits and risks in biggest study-of-its-kind

"Americans deserve to know the quality of the products they are buying and deserve drugs that have been proven to be safe and effective," an HHS spokesperson told Scientific American in response to questions about Kennedy's comment and the timing of the lift. "The FDA's goal is to ensure that patients can obtain FDA-approved products, and when those aren't available or can't work because of a patient's unique situation, are made by licensed U.S. pharmacies."

But even if Kennedy's plan to make some peptides easier to compound in the U.S. is enacted, it does not necessarily mean the drugs are safe or effective. The FDA does not approve or review drugs from compounding pharmacies — it just monitors the active ingredients the facilities use.

If peptides become more readily available in the U.S. market, Cushman predicts, more "people are going to just start trying [them]" — whether there are data to back them up or not. The public may experience any benefits — and perils — of peptides before scientists quantify them in the clinic.

This article was first published at Scientific American . © ScientificAmerican.com . All rights reserved. Follow on TikTok and Instagram , X and Facebook .